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ABSTRACT
Objective To identify a core set of domains (outcomes)
to be measured in psoriatic arthritis (PsA) clinical trials
that represent both patients’ and physicians’ priorities.
Methods We conducted (1) a systematic literature
review (SLR) of domains assessed in PsA; (2)
international focus groups to identify domains important
to people with PsA; (3) two international surveys with
patients and physicians to prioritise domains; (4) an
international face-to-face meeting with patients and
physicians using the nominal group technique method to
agree on the most important domains; and (5)
presentation and votes at the Outcome Measures in
Rheumatology (OMERACT) conference in May 2016. All
phases were performed in collaboration with patient
research partners.
Results We identified 39 unique domains through the
SLR (24 domains) and international focus groups (34
domains). 50 patients and 75 physicians rated domain
importance. During the March 2016 consensus meeting,
12 patients and 12 physicians agreed on 10 candidate
domains. Then, 49 patients and 71 physicians rated
these domains’ importance. Five were important to
>70% of both groups: musculoskeletal disease activity,
skin disease activity, structural damage, pain and
physical function. Fatigue and participation were
important to >70% of patients. Patient global and
systemic inflammation were important to >70% of
physicians. The updated PsA core domain set endorsed
by 90% of OMERACT 2016 participants includes
musculoskeletal disease activity, skin disease activity,
pain, patient global, physical function, health-related
quality of life, fatigue and systemic inflammation.
Conclusions The updated PsA core domain set
incorporates patients’ and physicians’ priorities and
evolving PsA research. Next steps include identifying
outcome measures that adequately assess these
domains.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory
disease with heterogeneous manifestations affecting
the skin, nails, peripheral joints, spine and entheses.
PsA can have a broad and profound impact on
quality of life.1 2 However, PsA life impact is not
fully assessed by the outcome measurement tools
used in current randomised controlled trials
(RCTs).3 Furthermore, most of these tools have
been adapted from studies in rheumatoid arthritis
and may not accurately reflect the whole experience
of patients with PsA.4
A PsA core set of domains to be measured in PsA
RCTs and longitudinal observational studies (LOS)
was originally developed by the Group for
Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) and endorsed by the Outcome
Measures in Rheumatology (OMERACT) in 2006.5
Since then, the science of outcomes research and
our knowledge of PsA have both significantly
evolved. First, the inclusion of patient research
partners (PRPs) and other relevant stakeholders is
now highly recommended in all stages of the
research process by both OMERACT6 and the
European League Against Rheumatism 7 as well as
regulatory agencies in the USA and Europe.
Additionally, OMERACT has updated its recom-
mendations for developing disease core sets and
published a core set development process map, the
OMERACT Filter 2.0,6 which was endorsed in
2014. Concurrently, along with methodological
developments, there has been much progress in PsA
treatment with three new classes of targeted thera-
peutics approved in the past three years.8 9 Recent
PsA RCTs assessed therapeutic efficacy not only by
traditional outcomes centred on peripheral arth-
ritis, but also additional measures of PsA manifesta-
tions (eg, systemic inflammation, enthesitis,
dactylitis, structural damage, nail disease and the
spine) and life impact (eg, fatigue, productivity).10
These were considered important in the 2006 PsA
core domain set but not essential to measure in all
RCTs either due to insufficient data to support
measurement or due to the absence of validated
outcome measures.5 11
The objective of the GRAPPA-OMERACT PsA
working group was to develop consensus, at an
international level, among patients and physicians
on a core set of domains to be measured in PsA
RCTs and LOS. Based on the methodological
framework of OMERACT Filter 2.0,6 we designed
research work streams to generate patient-relevant
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and physician-relevant domains and then arrive at consensus on
PsA domains reflective of stakeholder perspectives.
METHODS
We conducted a systematic literature review (SLR) of domains
assessed in PsA RCTs, LOS and registries, international qualita-
tive focus groups, two international web-based surveys with
patients and physicians, and an international face-to-face con-
sensus meeting with patients and physicians using the nominal
group technique (NGT) to agree on domains most important to
all participants. PRPs were included in all phases of the
process.12 Results were presented at the OMERACT conference
in May 2016 in British Columbia, Canada and discussed in a
plenary workshop and small groups. A diagram of the research
process is represented in figure 1.
Systematic literature review
An SLR was performed to identify all domains (or outcomes)
measured in PsA RCTs, LOS and registries from 2010 to
2015.10 A previous SLR reviewed the PsA outcomes used in the
previous 5-year interval.13
International focus groups
Focus groups were conducted to identify domains important to
patients with PsA.14 Two qualitative research studies were con-
ducted independently and in parallel with patients with PsA to
identify outcomes important to them: a focus group study
across six countries (Australia, Brazil, France, Netherlands,
Singapore, the USA); and a multicentre UK focus group study.
Participants met Classification Criteria for Psoriatic Arthritis15
and were sampled across the spectrum of PsA manifestations,
activity and demographic characteristics. After informed consent
was obtained, qualified facilitators (two per group) led a semi-
structured discussion following a focus group guide agreed upon
by the investigators in advance. Each focus group was audio-
recorded and transcribed verbatim. Transcripts were immedi-
ately translated into English and proofread with a native speaker
to assist in translation as needed.16 Investigators on both teams
included PRPs in study conception, conduct and data analysis.
Qualitative data analysis was completed independently by each
team using inductive thematic analysis17 to identify domains
and domain definitions based on focus group participants’
descriptions.
International surveys among patients and physicians
Domains from the focus group studies and the SLR were com-
bined into a single list of domains. Definitions were assembled
using focus group participants’ descriptions and reviewed by the
working group including PRPs to ensure that patient partici-
pants would easily understand domains. Web-based surveys
were then administered to patients and physicians (separate
surveys running in parallel) to rate domains for importance.
Patient participants were recruited from clinics at five sites and
PsA patient organisations. Patients were purposefully selected to
represent all phenotypes of PsA including varied levels of skin
disease, joint disease, disease manifestations, age and gender.
Physician participants were purposefully selected from GRAPPA
members to include both rheumatologists and dermatologists,
representative of different parts of the world, age and gender
groups. Patient surveys were administered in English, except to
French patient participants who received the survey translated
in French. REDCap (V.6.13.3) software18 was used for survey
administration, data collection and management. Participants
received an introduction about the project objectives and were
asked to rate each domain on an 11-point numerical rating scale
from 0, ‘not important at all’, to 10, ‘very important’. Survey
results for the patient and physician groups were separately sum-
marised as mean, median and percentage of respondents who
rated each domain in one of three categories of importance (≤3,
4–7 and ≥8). Each domain was then assigned to one of three
categories reflecting levels of agreement: (A) important for both
groups (>50% in each group voted the domain as ≥8); (B)
important for one group but not for the other group (>50%
voted the domain as ≥8 in one group and >50% voted the
domain as <8 in the other); and (C) less important for both
groups (>50% in both groups voted the domain as <8).
Face-to-face consensus meeting
In total, 12 patients, 12 physicians and 2 non-voting fellows
were invited to participate in a face-to-face consensus meeting
held on 12 March 2016 in Jersey City, New Jersey, USA. An
independent expert in consensus methods ( JAS) moderated the
meeting using the NGT. The NGT is a rigorously structured
meeting conducted to allow a group of key stakeholders to iden-
tify and rate a list of priorities while ensuring the inclusion of
Figure 1 Study diagram: research work streams that led to the
updated psoriatic arthritis (PsA) core domain set are represented: the
process started with a systematic literature review (SLR) and
international focus groups with patients with PsA to generate a large
pool of candidate domains. These were then reduced through an
iterative consensus process consisting of surveys with patients and
physicians, a consensus nominal group technique (NGT) meeting with
patients and physicians, and breakout group discussions and voting at
the Outcome Measures in Rheumatology (OMERACT) 2016.
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all participants’ opinions.19 The objective of the meeting was to
agree on a preliminary core set of the 7–10 most important
domains for both patients and physicians to be measured in PsA
RCTs and LOS. The goal number of domains was established a
priori after considering feasibility and other examples of disease
core sets.20
For patients, a separate introduction was held the evening
before the meeting to familiarise them with the objectives, and
the consensus process as well as domains and definitions. The
consensus meeting began with an introduction to OMERACT
Filter 2.0 and presentation of results from the research work
streams. Participants were informed that according to the meth-
odological framework used (OMERACT Filter 2.0) the availabil-
ity and applicability of outcome measurement instruments were
not relevant to the domain discussion and this was reinforced
throughout the meeting. The NGT process started with discus-
sion of domains that were in category C (described above) with
the purpose to discard them or move them into category
B. Next items were moved from category B into category A or
discarded. Then, the remaining items were discussed and main-
tained or merged into larger categories if agreed on by most
participants to help reduce the number of domains.
Anonymised votes on agreement with domain placement were
conducted as needed on coloured index cards to distinguish
patients and physicians and allow reporting of results by group
and not by majority alone. At the end of the meeting, a prelim-
inary core set of domains for PsA was drafted and presented to
the group.
Second international surveys with patients and physicians
Following the consensus meeting, a second round of web-based
surveys was conducted among the same patients and physicians
who were invited to participate in the first survey. Participants
were asked to rate the importance of each domain in the prelim-
inary PsA core domain set using the same 11-point numerical
rating. Results of the survey reported for patients and physicians
separately as mean, median and percentage of respondents
rating items as important (defined as score ≥8).
OMERACT endorsement
The PsA Workshop was held at the 2016 OMERACT
Conference in Whistler, British Columbia, Canada.21 The work
above was presented, breakout groups discussed the domains
proposed, and finally, OMERACT participants voted for individ-
ual domains as well as the final core domain set (Orbai AM, de
Wit M, Mease PJ, et al. Updating the psoriatic arthritic core
domain set: a report from the PsA workshop at OMERACT
2016. The J Rheumatol 2016 (submitted)).
RESULTS
Candidate domains
Twenty-four domains were obtained from the SLR of outcomes
measured in PsA RCTs, LOS and registries. Measurement of the
complete 2006 PsA core domain set increased in RCTs con-
ducted 2010–2015 compared with 2006–2010. Recent RCTs
frequently measured domains in addition to the core set; and
among RCTs, there was great heterogeneity in outcome measure
selection per domain.
The focus group study consisted of 16 focus groups with 89
participants with PsA on five continents represented by six
countries (number of focus groups in each country): the USA
(5), Brazil (3), Australia (2), France (2), the Netherlands (2) and
Singapore (2). The UK focus group study consisted of eight
focus groups with 41 participants. Thirty-five domains and cor-
responding definitions were obtained from qualitative data ana-
lysis of international PsA focus group transcripts.
Combining domains from the SLR and focus group studies
resulted in a list of 39 unique domains (table 1). The domains
and definitions were reviewed for clarity by the working
group (seven physicians, five PRPs, two fellows and one
methodologist).
International patient and physician survey results
The survey was administered to 100 patients and 124 physi-
cians. In total, 50 patients (50%) and 75 physicians (60%) com-
pleted the survey. Patient respondents were 64% female and age
groups (years) 2% (18–25), 36% (26–45), 52% (46–65) and
10% above 65. Physician respondents were 92% rheumatolo-
gists and 8% dermatologists, 61% male, and age groups (years)
33% (26–45), 60% (46–65) and 7% (above 65). Results are
summarised in table 2 for each of the 39 domains. Based on
percentage votes into each category of importance, domains
were organised into agreement categories A, B or C ((A) import-
ant for both groups (>50% in each group voted the domain as
≥8); (B) important for one group but not for the other group
(>50% voted the domain as ≥8 in one group and >50% voted
the domain as <8 in the other); and (C) less important for both
groups (>50% in both groups voted the domain as <8)).
Consensus meeting summary
During the NGT process, participants regrouped or redefined
some items from the list of 39 domains. For example, emotional
well-being captures depressive mood, anxiety, embarrassment,
self-worth, frustration and stress. Participation includes family
roles, social activities, leisure activities and employment. As part
of the discussion related to combining these elements, partici-
pants referred to the International Classification of Functioning
(ICF) distinction between activity and participation. In the ICF,
‘activities’ encapsulates the ability to perform a task or action by
an individual; ‘participation’ is the ability to be involved in life,
to perform societal tasks and responsibilities, to work, to take
part in social events, leisure and family life.22 The musculoskel-
etal (MSK) manifestations of PsA (peripheral joint activity, dac-
tylitis, enthesitis and spondylitis) were grouped under the larger
concept of MSK disease activity. Similarly, skin activity was
defined as including both skin and nail disease.
The concept of health-related quality of life (HRQoL),
present in the 2006 PsA core domain set and potentially over-
lapping with some of these domains, was brought up for discus-
sion. Participants agreed that aspects of physical, emotional and
social life are included in HRQoL. However, patients unani-
mously favoured the inclusion of specific domains in the core
set (emotional well-being, fatigue, pain, participation, physical
function) over the broad concept of HRQoL. The patient global
assessment of disease was also discussed. While there was
general agreement to not discuss instruments, little is under-
stood about what the ‘patient global assessment’ measures are.
The concept was felt to reflect disease activity but also an over-
arching global health status of the patient, specific to that
patient. As a result of this discussion, global health was renamed
patient global defined as patient global assessment of
disease-related health status and maintained as a core domain.
Structural joint damage was voted important by both groups.
However, in the meeting, there was a debate whether or not it
should be required in all RCTs and LOS or designated as
important but not required for each clinical trial. Discussions
were focused on three main points: (1) one of the main
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objectives of disease-modifying therapy in PsA is to ultimately
prevent structural damage and not only symptoms; (2) the use
of current imaging procedures, especially more sensitive ones
like MRI, is costly; and (3) it is difficult to demonstrate a signifi-
cant difference in structural damage in RCTs of short duration.
The final decision was to include structural damage with the
specification that evidence for inhibition of structural damage
should be required at least once during the development
programme of a new medication but not required in all RCTs
and LOS.
At the end of the consensus meeting, 10 domains were agreed
on as important and proposed for inclusion in the PsA core
domain set for clinical trials: MSK disease activity, skin disease
activity, pain, patient global, physical function, participation,
emotional well-being, fatigue, systemic inflammation and struc-
tural damage (with the specification that this is recommended
for inclusion at least once during a PsA drug development pro-
gramme). Economic cost was recommended as important but
not essential to be measured in all clinical trials. Items placed on
the PsA group research agenda due to their importance to
Table 1 Candidate psoriatic arthritis domains and definitions
Domain Definition*
1 Anxiety Being concerned, worried, fearful or anxious
2 Cognitive function Being able to concentrate and remember things (concentration and memory issues)
3 Coping Being able to deal with the social and emotional impact of the disease on oneself (includes managing stress, embarrassment)
4 Daily activities including
housework
Being able to fulfil housework tasks, shopping, other necessary daily activities
5 Dactylitis Sausage finger or toe, full thickness inflammation of a digit or toe
6 Depressive mood Feeling sad, feeling down or sorry for oneself or feeling depressed
7 Discomfort Experiencing noticeable physical issues/discomfort, which are not pleasant but not causing pain
8 Disease activity Presence of disease symptoms
9 Embarrassment Experiencing awkward self-consciousness or embarrassment in public or social situations
10 Emotional support Availability of emotional support from family members and friends
11 Emotional well-being Feeling good about oneself
12 Employment/work Being able to perform activities related to work/employment
13 Enthesitis Pain and inflammation at the site of a tendon bone interface (tendon insertions on bone)
14 Family roles Relationships with family and close friendships (includes parenthood, marriage)
15 Fatigue Experiencing fatigue, tiredness, lack of energy, feeling worn out or exhausted
16 Financial impact Experiencing financial loss due to treatment cost, work loss, early retirement, cost of assistive devices, etc
17 Frustration Being annoyed or upset about not being able to achieve what one wishes
18 Global health The overall health status of the patient
19 Independence Being able to maintain one’s independence, not being dependent on others for help
20 Intimacy and sexual relations Satisfaction with intimate relationships
21 Leisure activities Being able to engage in leisure activities
22 Medication side effects Experiencing undesired secondary effects from taking psoriatic arthritis medications
23 Nail psoriasis Having discoloured, lifting, pitted nails affected with psoriasis
24 Pain Experiencing an unpleasant physical sensation that aches, hurts in one or more joints or the spine
25 Participation in social activities Ability to participate in social activities
26 Structural joint damage Join deformity, damage, instability to one or more joints or the spine
27 Physical function Being able to perform physical activities (includes upper/lower extremity functioning, balance)
28 Psoriasis symptoms Experiencing itching, dryness, pain, plaques, thickness, cracks, bleeding, scaling of affected skin including genital areas and the scalp
29 Self-management Being able to effectively decrease or minimise the physical impact of disease on oneself (eg, choice of non-pharmacological
interventions, prevention of disease worsening, use of aids, diet, lifestyle, pacing, relaxation etc)
30 Self-worth Shame, self-esteem, feeling accepted or rejected by others (can range from feeling valued to feeling helpless, useless, ashamed, guilty or
rejected)
31 Sleep quality Being able to have a restful sleep
32 Social support Availability of family members and friends for help
33 Spine symptoms Back/spine symptoms of pain, stiffness
34 Stiffness Experiencing resistance or rigidity in one or more joints, tendons or the spine, which prevents smooth and full range of motion
35 Stress Feeling under pressure and under tension
36 Swelling Enlargement of one or more joints
37 Systemic inflammation Blood test such as the acute-phase reactants ESR and/or C reactive protein
38 Treatment burden Impact of treatment and monitoring of disease or treatment (eg, financial or time commitment)
39 Unpredictability of disease
activity
Uncertainty in the short term of being symptom free or able to engage in activities
Domains appear in alphabetical order.
*Domain definitions represent focus group participants’ descriptions of the corresponding domain and were reviewed by the working group.
ESR, erythrocyte sedimentation rate.
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patients but unclear contribution to measuring response in
RCTs and LOS were independence, sleep, stiffness and treat-
ment burden. Specific details on each domain discussion and
their movement among categories during the consensus meeting
are provided in online supplementary table S1. The preliminary
PsA domain structure at the conclusion of the consensus
meeting is represented in online supplementary figure S1.
Second international patient and physician survey
A second survey was administered to 100 patients and 124 phy-
sicians to rate the importance of each domain agreed on in the
consensus meeting. In total, 49 patients (49%) and 71 physi-
cians (57%) completed the survey. Results are summarised in
online supplementary table S2. Survey respondents agreed with
the proposed core domain set drafted at the consensus meeting,
with the exception of emotional well-being, which was rated
important by <70% of both patients and physicians in the
second survey. Figure 2 summarises results from both survey
rounds.
Endorsement of the PsA core domain set
Based on discussions and voting at the biannual OMERACT
meeting (2016), participation and structural damage in the pre-
liminary core set were moved to the middle circle (strongly
recommended but not mandatory for all RCTs and LOS). The
updated 2016 PsA domain set achieved consensus with a 90%
vote from 130 OMERACT participants. The 2016 PsA core
domain set includes the following outcomes recommended for
assessment in all RCTs and LOS (inner core): MSK disease activ-
ity, skin disease activity, pain, patient global, physical function,
HRQoL, fatigue and systemic inflammation. In addition, the fol-
lowing outcomes (middle circle) are strongly recommended but
these may not be feasible in all RCTs and LOS: economic cost,
emotional well-being, participation and structural damage.
Outcomes that need to be studied further due to their import-
ance for people with PsA include independence, sleep, stiffness
and treatment burden. The updated 2016 PsA core domain set
is represented in figure 3. All areas of the OMERACT Filter 2.0
framework (pathophysiology, life impact and resource utilisa-
tion) have been addressed by this core domain set.
The 2016 core domain set builds on the first PsA core
domain set crafted in 2006.5 Major changes include the move-
ment of fatigue to the inner core and inclusion of participation
and emotional well-being as strongly recommended but not
mandatory domains for measurement. Additionally, enthesitis
and dactylitis are now part of the inner core and are combined
with peripheral arthritis as MSK disease activity.
DISCUSSION
In this article, we report the development of the 2016
OMERACT-endorsed PsA core domain set and the steps taken
to reach consensus among patients and physicians. The patient
perspective was integrated throughout each phase of the
research. The qualitative research components and PRP involve-
ment at each step give validity to the resulting proposed
domains for PsA clinical trials.14 The sampling process was
inclusive of patients from five continents, with a broad spectrum
of PsA manifestations, varied levels of disease activity and socio-
demographic characteristics, which increases generalisability of
our findings.
Our findings confirm the previously demonstrated broad life
impact of PsA. Critical elements of life impact for patients with
PsA are fatigue, participation and emotional well-being.23
Fatigue was previously recommended for measurement in all
PsA RCTs.24 While fatigue has been measured in only approxi-
mately one-third of RCTs,12 it has been demonstrated to
improve with effective therapy.25–27 Aspects of participation and
emotional well-being also have been demonstrated to improve
to approximate matched norms with biological therapy for
Table 2 Domain ratings by patients and physicians and
corresponding agreement categories in the first survey
Ratings
Patients, N=50 Physicians, N=75
Category*≤3 4–7 ≥8 ≤3 4–7 ≥8
Domains and corresponding group % for each category of ratings
Anxiety 30 40 30 41 41 17 C
Cognitive function 30 28 42 41 47 12 C
Coping 16 42 44 28 36 36 C
Daily activities including
housework
10 18 72 1 35 64 A
Dactylitis 18 22 60 3 13 84 A
Depressive mood 16 38 44 17 51 32 C
Discomfort 12 40 48 16 52 32 C
Disease activity 4 32 64 1 16 83 A
Embarrassment 30 42 28 24 45 31 C
Emotional support 22 30 48 33 52 15 B
Emotional well-being 10 30 60 24 48 28 B
Employment/work 4 20 76 3 21 76 A
Enthesitis 8 26 66 0 16 84 A
Family roles 12 32 56 25 53 21 B
Fatigue 0 22 78 4 33 63 A
Financial impact 20 32 48 23 43 35 C
Frustration 18 36 46 33 45 21 C
Global health 8 24 68 5 24 71 A
Independence 8 10 82 20 42 37 B
Intimacy and sexual
relations
24 34 42 24 47 29 C
Leisure activities 2 38 60 11 61 28 B
Medication side effects 4 26 70 11 24 65 A
Nail psoriasis 22 34 44 8 25 67 B
Pain 4 20 76 1 11 88 A
Participation in social
activities
6 38 56 12 52 36 B
Physical function 4 24 72 0 17 83 A
Psoriasis symptoms 10 32 58 1 17 81 A
Self-management 4 38 58 17 52 31 B
Self-worth 22 40 38 32 40 28 C
Sleep quality 8 26 66 12 49 39 B
Social support 16 48 36 31 57 12 C
Spine symptoms 14 22 64 1 21 77 A
Stiffness 2 32 66 1 36 63 A
Stress 14 36 50 32 52 16 B
Structural joint damage 8 24 68 1 21 77 A
Swelling 14 22 64 4 13 83 A
Systemic inflammation 22 34 44 8 23 69 B
Treatment burden 6 48 46 19 55 27 C
Unpredictability of disease
activity
10 36 54 31 44 25 B
Light grey cells were rated by >50% of participants. Darker grey cells with bolded font
were rated as important by ≥70% of participants.
*Categories were defined as (A) important for both groups (>50% in each group voted
the domain as ≥8); (B) important for one group but not for the other group (>50%
voted the domain as ≥8 in one group and >50% voted the domain as <8 in the other);
(C) less important for both groups (>50% in both groups voted the domain as <8).
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PsA.2 Measurement of participation and emotional well-being
needs to be explored for use in PsA RCTs and might in the
future, together with fatigue, replace the generic construct of
HRQoL. In addition to life impact, the core domain set we
propose also emphasises the importance of measuring all facets
of the pathophysiology of PsA, including enthesitis, dactylitis,
spine and nail disease. These are all disabling elements of the
disease but often considered secondary to the peripheral arth-
ritis classically associated with PsA.9 Systemic inflammation is
similarly highlighted as it may lead to increased morbidity and
mortality through comorbidities such as cardiovascular disease
and diabetes.28 29
Strengths of this study include an international representation
of PsA patient participants in focus groups and international
representation of patient and physician stakeholders who parti-
cipated in the surveys and consensus meeting. We followed
rigorous research methods, had equal representation of patients
and physicians at the consensus meeting and involved PRPs in
each step of the process. However, our study also had limita-
tions. Surveys were only in English and French, and therefore,
limited selection of patients to those speaking one of these lan-
guages in the international web-based surveys. Similarly, the
consensus meeting was conducted in English and limited to
English-speaking international patients and physicians. On the
contrary, the international focus groups were conducted in the
native language and translated by linguistically and culturally
competent translators with review by native coinvestigators.
International focus group participants were sampled across PsA
manifestations, disease activity and duration and socioeconomic
status. This ensured that we captured broad content early on in
the process of data collection and obtained domains that are
generalisable to people with PsA worldwide.
This study confirms that patients’ and physicians’ priorities are
different. A core domain set with face validity should capture the
diversity of stakeholder perspectives.6 30 We demonstrated that
the inclusion of patient and physician perspectives is possible
using a data-driven process and ensuring awareness of both
Figure 2 Domains important to patients and physicians for inclusion in psoriatic arthritis (PsA) clinical trials: The first panel shows domains
selected important* by >70% of either patients or physicians in the first international survey and patient and physician percentages. The second
panel shows patient and physician percentages rating each domain as important* in the second international survey (*important was designated as
receiving a rating of ≥8 on a numerical rating scale from 0, not important at all, to 10, very important). The brackets identify the 70% level of
consensus within a group. MSK, musculoskeletal.
Figure 3 Updated 2016 psoriatic arthritis (PsA) core domain set.
Musculoskeletal (MSK) disease activity includes peripheral joints,
enthesitis, dactylitis and spine symptoms; skin activity includes skin and
nails; patient global is defined as patient-reported disease-related
health status. The inner circle (core) includes domains that should be
measured in all PsA randomised controlled trials (RCTs) and
longitudinal observational studies (LOS). The middle circle includes
domains that are important but may not be feasible to assess in all
RCTs and LOS. The outer circle or research agenda includes domains
that may be important but need further study.
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perspectives throughout the development of a core outcome set.
Next steps are examining outcome measures’ psychometric prop-
erties for measuring each core set domain and selecting a core set
of outcome measures that are adequate and not redundant.
In conclusion, patients and physicians include both disease
manifestations and aspects of life impact when identifying the
domains of importance in PsA. RCTs and observational studies
measuring and reporting these outcomes will better represent
the heterogeneity of PsA and the impact of therapy on its varied
manifestations. Such data will be the starting point to frame
treatment discussions and shared decision-making between
patients and physicians and address desired therapy selection on
an individual basis.
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